The introduction of biological agents targeting core inflammatory components of the disease, including tumor necrosis factor-alpha (TNFa) inhibitors, and the interleukin (IL)-12/IL-23 inhibitor ustekinumab, IL-17 and IL-23 inhibitors, has greatly improved the management of psoriasis and, therefore, patients’ quality of life (QoL) [8]. This evidence concerns the gene IL17A and psoriasis.